Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor

被引：40

作者：

Hajji, N ^{[1
]}

Mateos, S ^{[1
]}

Pastor, N ^{[1
]}

Domínguez, I ^{[1
]}

Cortés, F ^{[1
]}

机构：

[1] Univ Seville, Fac Biol, Dept Cell Biol, E-41012 Seville, Spain

来源：

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS | 2005年 / 583卷 / 01期

关键词：

aclarubicin; topoisomerase II; topoisomerase I; cytotoxicity; DNA damage;

D O I：

10.1016/j.mrgentox.2005.01.012

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];

摘要：

The anthracycline aclarubicin (ACLA) is an intercalative antibiotic and antineoplastic agent that efficiently binds to DNA, leading to a secondary inhibition of the catalytic activity of topoisomerase II (topo II) on DNA. Besides this activity, ACLA has been reported to exert a concomitant poisoning effect on topo I, in a fashion similar to that of the antitumor drug camptothecin and its derivatives. As a consequence of this dual (topo II catalytic inhibiting/topo I poisoning) activity of ACLA, the picture is somewhat confusing with regards to DNA damage and cytotoxicity. We studied the capacity of ACLA to induce catalytic inhibition of topo II as well as cytotoxic effects and DNA damage in cultured Chinese hamster V79 cells and their radiosensitive counterparts irs-2. The ultimate purpose was to find out whether differences could be observed between the two cell lines in their response to ACLA, as has been widely reported for radiosensitive cells treated with topo poisons. Our results seem to agree with the view that the radiosensitive irs-2 cells appear as hypersensitive ACLA as compared with radiation repair-proficient V79 cells. The recovery after ACLA treatment was also followed-up, and the irs-2 mutant was found to be less proficient than V79 to repair DNA strand breaks induced by ACLA. (c) 2005 Elsevier B.V. All rights reserved.

引用

页码：26 / 35

页数：10

共 39 条

[1]

Catalytic inhibitors of DNA topoisomerase II [J].

Andoh, T ;

Ishida, R .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1400 (1-3) :155-171

[2]

BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3

[3]

MUTANT RODENT CELL-LINES SENSITIVE TO ULTRAVIOLET-LIGHT, IONIZING-RADIATION AND CROSS-LINKING AGENTS - A COMPREHENSIVE SURVEY OF GENETIC AND BIOCHEMICAL CHARACTERISTICS [J].

COLLINS, AR .

MUTATION RESEARCH, 1993, 293 (02) :99-118

[4]

Induction of endoreduplication by topoisomerase II catalytic inhibitors [J].

Cortés, F ;

Pastor, N .

MUTAGENESIS, 2003, 18 (02) :105-112

[5]

CYTOGENETIC EFFECTS OF INHIBITION OF TOPOISOMERASE-I OR TOPOISOMERASE-II ACTIVITIES IN THE CHO MUTANT EM9 AND ITS PARENTAL LINE AA8 [J].

CORTES, F ;

PINERO, J ;

PALITTI, F .

MUTATION RESEARCH, 1993, 288 (02) :281-289

[6]

ISOLATION AND PARTIAL CHARACTERIZATION OF A MAMMALIAN-CELL MUTANT HYPERSENSITIVE TO TOPOISOMERASE-II INHIBITORS AND X-RAYS [J].

DAVIES, SM ;

DAVIES, SL ;

HALL, AG ;

HICKSON, ID .

MUTATION RESEARCH, 1990, 235 (02) :111-118

[7]

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103 [J].

Etiévant, C ;

Kruczynski, A ;

Barret, JM ;

Perrin, D ;

van Hille, B ;

Guminski, Y ;

Hill, BT .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (02) :101-113

[8]

TOPOISOMERASE POISONS - HARNESSING THE DARK SIDE OF ENZYME MECHANISM [J].

FROELICHAMMON, SJ ;

OSHEROFF, N .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (37) :21429-21432

[9]

Gatto B, 1999, CURR PHARM DESIGN, V5, P195

[10]

Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage [J].

Gieseler, F ;

Bauer, E ;

Nuessler, V ;

Clark, M ;

Valsamas, S .

LEUKEMIA, 1999, 13 (11) :1859-1863

← 1 2 3 4 →